A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

June 15, 2023

Study Completion Date

January 16, 2024

Conditions
HIV Infections
Interventions
DRUG

Dual Therapy

DTG + 3TC

DRUG

Triple therapy

BIC / FTC / TAF

Trial Locations (18)

26006

Hospital San Pedro, Logroño

28002

Hospital Universitario Príncipe de Asturias, Alcalá de Henares

28050

Hospital Universitario Infanta Leonor, Madrid

28222

Hospital Universitario Puerta de Hierro, Majadahonda

30003

H. General Universitario Reina Sofía, Murcia

46026

H. Universitario y Politécnico La Fe, Valencia

Unknown

Hospital de Bellvitge, Barcelona

Hospital Univ. Vall D'Hebron, Barcelona

H. General Universitario Guadalajara, Guadalajara

Hospital Clínico San Carlos, Madrid

Hospital Fundación Jimenez Diaz, Madrid

Hospital Univ. La Paz, Madrid

Hospital Univ. Ramón y Cajal, Madrid

Hospital Virgen de las Nieves, Malá

Hospital Virgen de la Victoria, Málaga

Hospital Univ. Virgen del Rocio, Seville

Hospital Univ. Clínico de Valencia, Valencia

Hospital Univ. Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Fundacion SEIMC-GESIDA

OTHER

NCT04076423 - A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection | Biotech Hunter | Biotech Hunter